Beijing Bohui Innovation Biotechnology Group Co Ltd. Sees Surge After Clinical Trial Approval
The Shenzhen‑listed health‑care equipment manufacturer, Beijing Bohui Innovation Biotechnology Group Co Ltd. (stock code SZ300318), recorded a sharp 20 % jump to its 20‑centimeter limit on November 12, 2025, as investors reacted to the approval of a clinical trial for a new vaccine developed by its wholly‑owned subsidiary.
Clinical Trial Approval Sparks Market Momentum
Late on November 11, Bohui Innovation announced that its controlled subsidiary Bohui Biopharmaceutical Co. Ltd. and partner Beijing Baishui Biotechnology Co. Ltd. had jointly applied for and received a “Drug Clinical Trial Approval Notice” from the China National Medical Products Administration (NMPA). The approval concerns a frozen‑dry vaccine for Haemophilus influenzae type b (Hib), a bacterial pathogen that can cause severe respiratory infections and meningitis, especially in children.
The NMPA’s endorsement allows the vaccine to enter human clinical testing, a critical milestone that signals the company’s progress toward a potential new product offering and expands its portfolio beyond its established in‑vitro diagnostic platform.
Investor Response and Sector‑Wide Rally
The announcement triggered a rapid price run at the open, with the stock closing at 7.20 CNY, its highest level since April 13, 2025, and a 20 % increase from the previous day. The 20‑centimeter limit—one of the highest permissible price changes in the Shenzhen market—was achieved in a matter of minutes, reflecting robust demand from both retail and institutional participants.
The move was part of a broader influenza‑related rally that has seen several stocks in the sector hit the 20‑centimeter ceiling. Other names such as Panlong Pharmaceutical, ST Three Saints, and Enwei Pharmaceutical also posted limit‑up gains. The rally follows the Chinese Center for Disease Control and Prevention’s forecast that the autumn‑winter influenza peak could occur in mid‑December to early January, raising expectations for vaccine development and sales.
Company Profile and Market Context
Founded in 2001, Bohui Innovation has established itself as a leading provider of in‑vitro diagnostic equipment, including human element detection systems, vitamin D test kits, infectious pathogen detection systems, atomic absorption spectrometers, and diarrheal virus detection kits. Its 2025 market capitalization is approximately 4.85 billion CNY, and the company trades on the Shenzhen Stock Exchange under the ticker SZ300318.
The company’s P/E ratio of –101.02 indicates that it is operating at a loss, a common situation for firms heavily invested in research and development. Nevertheless, the recent vaccine approval injects optimism about future revenue streams and could help improve its earnings profile once the product reaches commercialization.
Outlook
The approval of the Hib vaccine trial is expected to:
- Accelerate Bohui Innovation’s product pipeline, providing a new revenue source that complements its diagnostic business.
- Bolster investor confidence in the company’s R&D capabilities, potentially supporting sustained share price appreciation.
- Position the firm to capitalize on the predicted influenza season, as demand for novel vaccines could rise sharply.
Analysts will monitor the trial’s progress, regulatory milestones, and any subsequent market activity, while investors may look to balance the upside potential against the company’s current loss‑making status and the volatility inherent in the Chinese equity market.
